Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Axsome Therapeutics (AXSM) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positi ...

Key Takeaways Biotech rally fueled by cheap valuations, strong EPS growth and FDA approvals; IBB beats SPY.Fed rate cuts, easy funding & macro tailwinds favor high-growth biotech stocks.M&A surge, capital revival lift biotech ETFs like IBB, XBI, CANC & IDNA.Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF (IBB) ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Liquidia Corporation (LQDA) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnin ...

Fortrea Holdings Inc. (FTRE) shares ended the last trading session 5.5% higher at $17.54. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.5% gain over the past four weeks.The sudden stock price rally reflects investors’ growing confidence in Fortrea Holdings’ ability to generate sustained revenues, underpinned by its global presence in nearly 100 countries and its expertise in comprehensive phase I – IV clinical ...

Group 1: Moderna Overview - Moderna's shares increased by 10.9% to close at $35.66, with trading volume significantly higher than usual, contributing to a total gain of 15% over the past four weeks [1] - BofA Securities raised its target price for Moderna from $21 to $24 while maintaining an Underperform rating, citing ongoing pressures from COVID-19 vaccine uptake [2] - The company is expected to report a quarterly loss of $2.79 per share, reflecting an 11.6% year-over-year decline, with revenues projected at $683.27 million, down 29.3% from the previous year [3] Group 2: Earnings Estimates and Trends - The consensus EPS estimate for Moderna has been revised 5.8% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] - Moderna holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the current market [4] - The stock belongs to the Zacks Medical - Biomedical and Genetics industry, which includes NovoCure, another company that saw a 3.8% increase in its stock price [4] Group 3: NovoCure Overview - NovoCure's consensus EPS estimate remains unchanged at -$0.39, representing a 36.1% improvement from the previous year [5] - NovoCure also holds a Zacks Rank of 3 (Hold), indicating a similar neutral market position as Moderna [5]

Key Takeaways Despite modest Q4 market gains, select ETF themes like silver, biotech and lithium sharply outperformed.Silver rally is supported by supply crunch and industrial demand, but rich valuations could limit upside.Biotech and lithium rally is supported by decent valuations, policy tailwind and strong demand outlooks.Wall Street put up a modest show in the final quarter of 2025, with the S&P 500 advancing only 1.9%, the Dow Jones gaining 3.3% and the Nasdaq Composite adding about 2.1%. The small-cap ...

Core Insights - Keros Therapeutics, Inc. (KROS) is currently rated as a Strong Buy (1) by Zacks Rank, while Novozymes A/S (NVZMY) is rated as a Sell (4), indicating a stronger earnings outlook for KROS compared to NVZMY [3] - KROS has a Value grade of A, while NVZMY has a Value grade of C, suggesting that KROS is perceived as a better investment opportunity based on valuation metrics [6] Valuation Metrics - KROS has a forward P/E ratio of 9.02, significantly lower than NVZMY's forward P/E of 26.74, indicating that KROS may be undervalued relative to NVZMY [5] - The PEG ratio for KROS is 0.38, which is lower than NVZMY's PEG ratio of 1.22, suggesting that KROS offers better value when considering expected earnings growth [5] - KROS has a P/B ratio of 0.75, compared to NVZMY's P/B ratio of 2.38, further supporting the notion that KROS is undervalued [6]

Core Insights - The iShares Biotechnology ETF (IBB) has experienced a significant rally of approximately 35% over the past six months, outperforming the SPDR S&P 500 ETF Trust (SPY), which increased by 12% during the same period [1] - The performance of the biotechnology sector marks a notable turnaround in 2025, contrasting with muted returns of 3.74% in 2024 and 0.97% in 2023 for the MSCI USA Pharmaceuticals, Biotechnology and Life Sciences Index [2] Performance Metrics - The Biomedical and Genetics industry has yielded returns of 12.7% and 6.8% over the past three and one-month periods, respectively, surpassing the S&P 500's performance of 3.9% over three months and a loss of 0.3% over the past month [3] Factors Driving the Rally - Biotech stocks are currently trading at cheaper valuations compared to the broader market, with the MSCI USA Pharmaceuticals, Biotechnology and Life Sciences Index at a forward P/E of 15.92X versus 23.25X for the MSCI USA index as of September 30, 2025 [5] - The Biomedical and Genetics industry has a forward P/E of 18.15X compared to the S&P 500's 19.43X, with a PEG ratio of 1.59X versus 2.17X for the S&P 500, and projected EPS growth of 22.38% compared to 7.33% for the S&P 500 [6] - Hopes for further Federal Reserve rate cuts are contributing to the rally, as biotech companies typically benefit from lower funding costs in a falling rate environment [7] - Recent regulatory developments, including Pfizer's agreement with the U.S. government to lower drug prices and invest $70 billion in the U.S., signal potential relief for the pharmaceutical industry [8][9] FDA Approvals - The FDA has approved numerous biotechnology drugs in 2025, including dordaviprone, sunvozertinib, and linvoseltamab-gcpt, with a total of 38 approvals recorded so far, following 50 in 2024 and about 55 in 2023 [10] Investment Activity - Biopharma venture investment reached $5.8 billion across 86 rounds in Q3 2025, totaling $17.1 billion year-to-date, with biopharma licensing valued at $63.7 billion in Q3 and $183.7 billion year-to-date [12] ETF Focus - Several biotech ETFs, including Invesco Biotechnology & Genome ETF (PBE), First Trust NYSE Arca Biotechnology ETF (FBT), Tema Oncology ETF (CANC), and Franklin Genomic Advancements ETF (HELX), are currently performing well, hovering around a one-month high [13]

Company Performance - TScan Therapeutics, Inc. reported a quarterly loss of $0.28 per share, which was better than the Zacks Consensus Estimate of a loss of $0.35, representing an earnings surprise of +20.00% [1] - The company posted revenues of $2.51 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 21.61%, compared to revenues of $1.05 million in the same quarter last year [2] - Over the last four quarters, TScan Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - TScan Therapeutics shares have declined approximately 59.9% since the beginning of the year, contrasting with the S&P 500's gain of 16.4% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.35 on revenues of $3.38 million, and for the current fiscal year, it is -$1.32 on revenues of $11.83 million [7] - The estimate revisions trend for TScan Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which TScan Therapeutics belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8]

Core Insights - Alkermes (ALKS) is currently viewed as a better value opportunity compared to Illumina (ILMN) based on various financial metrics and rankings [1][7] Valuation Metrics - Alkermes has a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook, while Illumina has a Zacks Rank of 3 (Hold) [3] - The forward P/E ratio for Alkermes is 16.69, significantly lower than Illumina's forward P/E of 25.86, suggesting that Alkermes may be undervalued [5] - Alkermes has a PEG ratio of 1.36, compared to Illumina's PEG ratio of 2.62, indicating a more favorable valuation relative to expected earnings growth [5] - The P/B ratio for Alkermes is 3.11, while Illumina's P/B ratio is 7.81, further supporting the notion that Alkermes is undervalued [6] - Based on these metrics, Alkermes has earned a Value grade of B, whereas Illumina has a Value grade of C [6] Earnings Outlook - Alkermes is noted for its improving earnings outlook, which enhances its attractiveness as a value investment [7]